Generation Bio Co. (GBIO) Stock Price, Quote & News

Company Profile

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-dri...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 655 7500

Website: generationbio.com

Address:

301 Binney Street, Cambridge, United States

Iightning Nov. 26 at 6:09 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 34.23% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:17 PM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 34.23% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 5:11 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 34.23% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 2:22 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 73.36% ROI | https://1ightning.com

0 · Reply

UgoGreg Nov. 21 at 3:23 PM

$GBIO https://youtu.be/BZgzOxUwjzc

0 · Reply

Iightning Nov. 21 at 5:44 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 73.36% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 3:42 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 73.36% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 11:20 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 73.36% ROI | https://1ightning.com

0 · Reply

breakeven2 Nov. 15 at 9:18 AM

$GBIO https://www.sec.gov/Archives/edgar/data/1733294/000200604525000004/xslSCHEDULE_13G_X01/primary_doc.xml

0 · Reply

smartkarma Nov. 11 at 3:09 AM

$GBIO | Strategic Reviews, Mergers, and Financing Updates: Key Developments in Biopharma, Hospitality "Generation Bio (GBIO) is undergoing a strategic review with potential outcomes including liquidation, reverse merger, or sale, with insiders owning 22%." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/strategic-reviews-mergers-and-financing-updates-key-developments-in-biopharma-hospitality

0 · Reply

Generation Bio Announces Third Quarter 2025 Financial Results

Oct 22, 2025, 4:05 PM EDT - 6 weeks ago

Generation Bio Announces CEO Transition

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

Jul 18, 2025, 8:35 AM EDT - 4 months ago

Generation Bio Announces 1-for-10 Reverse Stock Split

Jul 7, 2025, 4:05 PM EDT - 5 months ago

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

May 28, 2025, 6:59 AM EDT - 6 months ago

Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 4:05 PM EDT - 7 months ago

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

Apr 2, 2025, 6:59 AM EDT - 8 months ago

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

Mar 13, 2025, 4:05 PM EDT - 9 months ago

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 6:59 AM EST - 10 months ago

Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 6, 2025, 5:00 AM EST - 10 months ago

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Jan 6, 2025, 4:30 PM EST - 11 months ago

Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases

Oct 22, 2024, 6:59 AM EDT - 1 year ago

Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Generation Bio to Present at the 2024 Cantor Global Healthcare Conference

Aug 6, 2024, 6:59 AM EDT - 1 year ago

Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference

Jun 14, 2024, 6:59 AM EDT - 1 year ago

Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit

May 13, 2024, 4:05 PM EDT - 1 year ago

Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 9, 2024, 6:59 AM EDT - 1 year ago

Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting

Apr 22, 2024, 5:31 PM EDT - 1 year ago

Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Apr 2, 2024, 6:59 AM EDT - 1 year ago

Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 4:20 PM EST - 1 year ago

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 6:59 AM EST - 1 year ago

Generation Bio to Present at the 2024 TD Cowen Health Care Conference

Jan 3, 2024, 4:05 PM EST - 2 years ago

Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 29, 2023, 6:59 AM EST - 2 years ago

Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

Nov 9, 2023, 4:15 PM EST - 2 years ago

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

Oct 26, 2023, 6:59 AM EDT - 2 years ago

Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

Oct 20, 2023, 8:15 AM EDT - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)

Oct 18, 2023, 6:59 AM EDT - 2 years ago

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

Sep 19, 2023, 7:30 AM EDT - 2 years ago

Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference

Aug 2, 2023, 4:15 PM EDT - 2 years ago

Generation Bio Reports Second Quarter 2023 Financial Results

May 31, 2023, 7:30 AM EDT - 2 years ago

Generation Bio to Present at the 2023 Jefferies Healthcare Conference

May 10, 2023, 4:15 PM EDT - 2 years ago

Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

May 9, 2023, 4:15 PM EDT - 2 years ago

Generation Bio to Present at the JMP Securities Life Sciences Conference

Apr 11, 2023, 7:30 AM EDT - 2 years ago

Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

Apr 5, 2023, 7:30 AM EDT - 2 years ago

Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

Mar 23, 2023, 7:44 AM EDT - 2 years ago

Generation Bio, Moderna announce collaboration

MRNA

Mar 23, 2023, 7:02 AM EDT - 2 years ago

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

MRNA

Mar 21, 2023, 4:15 PM EDT - 2 years ago

Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

Feb 27, 2023, 7:30 AM EST - 3 years ago

Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference

Feb 23, 2023, 4:28 PM EST - 3 years ago

Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results

Jan 3, 2023, 4:30 PM EST - 3 years ago

Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 3, 2022, 4:15 PM EDT - 3 years ago

Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results

Sep 22, 2022, 7:30 AM EDT - 3 years ago

Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Sep 20, 2022, 7:30 AM EDT - 3 years ago

Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

Aug 4, 2022, 4:15 PM EDT - 3 years ago

Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results

Aug 2, 2022, 4:15 PM EDT - 3 years ago

Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference

Jul 18, 2022, 7:30 AM EDT - 3 years ago

Generation Bio Appoints Dannielle Appelhans to Its Board of Directors

Jun 2, 2022, 7:30 AM EDT - 3 years ago

Generation Bio to Present at the 2022 Jefferies Healthcare Conference

May 5, 2022, 4:15 PM EDT - 3 years ago

Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results

Iightning Nov. 26 at 6:09 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 34.23% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:17 PM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 34.23% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 5:11 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.07 | Profit: 34.23% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 2:22 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 73.36% ROI | https://1ightning.com

0 · Reply

UgoGreg Nov. 21 at 3:23 PM

$GBIO https://youtu.be/BZgzOxUwjzc

0 · Reply

Iightning Nov. 21 at 5:44 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 73.36% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 3:42 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 73.36% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 11:20 AM

1ightning® Options Trade Alert (Actionable) | Buy $GBIO Jan 16 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 73.36% ROI | https://1ightning.com

0 · Reply

breakeven2 Nov. 15 at 9:18 AM

$GBIO https://www.sec.gov/Archives/edgar/data/1733294/000200604525000004/xslSCHEDULE_13G_X01/primary_doc.xml

0 · Reply

smartkarma Nov. 11 at 3:09 AM

0 · Reply

JarvisFlow Nov. 10 at 9:41 AM

Needham has adjusted their stance on Generation Bio ( $GBIO ), setting the rating to Buy with a target price of 15.

0 · Reply

smartkarma Nov. 10 at 6:18 AM

$GBIO | Generation Bio's Strategic Review: Potential 50% Upside Amid Restructuring and Cash Management Challenges "Generation Bio's net cash is projected at $7.6/share, 50% above the current price, with limited ongoing cash burn." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/generation-bio-s-strategic-review-potential-50-upside-amid-restructuring-and-cash-management-challenges

0 · Reply

breakeven2 Nov. 6 at 8:00 AM

$GBIO No Comments on earnings Q3

0 · Reply

breakeven2 Nov. 4 at 7:25 AM

$GBIO 🙏🏼🙏🏼🙏🏼🙏🏼🙏🏼🙏🏼

0 · Reply

ka1954 Oct. 31 at 8:27 PM

$GBIO waiting to end of december or early 2026 now. end of year usually creates tax loss sellers

0 · Reply

Stockkkky Oct. 31 at 9:14 AM

$GBIO I'm sure with some kind of good news this stock can push back to it's 52 week high of 25$+ 🤷once some good news is out this stock can squeeze massively 🤷let's wait on news 😹

1 · Reply

DARKP00L Oct. 22 at 8:20 PM

$GBIO 16:09 on Oct. 22 2025 Generation Bio President, CEO Geoff McDonough To Become Board Chair, Effective Oct. 31; Yalonda Howze Names Interim CEO, President #tradeideas

0 · Reply

StockAlertzz Oct. 21 at 3:25 AM

$GBIO lol

0 · Reply

kshonstocks Oct. 16 at 1:59 PM

$GBIO has the higher highs Generation Bio (GBIO) Has $185M in Cash—Here’s Why That Matters https://biotechhealthx.com/biotech-news/generation-bio-gbio-has-185m-in-cash-heres-why-that-matters/

0 · Reply

S2K_TP Oct. 9 at 5:14 AM

$GBIO 6.60 breakout on watch 🚨

0 · Reply

Market Cap	34.43M
Revenue (ttm)	19.89M
Net Income (ttm)	-131.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-661.99%
Debt to Equity Ratio	0.00

Volume	27,700
Avg Vol	58,696
Day's Range	N/A - N/A
Shares Out	6.74M
Stochastic %K	64%
Beta	1.96
Analysts	Sell
Price Target	$9.33